Abstract:Background: The COVID-19 pandemic has exacerbated psychological challenges, leading to increased rates of clinically significant depression and suicidal ideation among MS patients. Despite advancements in MS treatments, there remains a need to investigate the impact of different drugs on the prevalence of suicidal ideation, particularly in the context of the pandemic. Method: This cross-sectional study, conducted in 2021, received ethics approval from the Ethics Committee of Kerman University of Medical Science. The study involved 234 MS patients selected from the MS Association in Kerman Province. Questionnaires were prepared and distributed via Google Drive and WhatsApp, with participants providing informed consent. The collected data were analyzed using SPSS software. Inclusion criteria encompassed adults diagnosed with MS according to specific criteria and willing to complete the questionnaires, while exclusion criteria included unclear diagnostic criteria and lack of cooperation. The instruments included a demographic questionnaire, medication checklist, and the Beck Suicidal Thought Scale questionnaire, which has been validated in Iran. Results: 202 MS patients completed the questionnaires, most of whom were women and married. The prevalence of Suicidal Ideation was 46.5 %, with 8.9 % at high risk. Factors such as gender, marital status, education, occupation, and city did not show statistically significant differences in SI. Patients with SI had a longer duration of illness and were more likely to have seen a psychiatrist. The COVID-19 pandemic affected the necessary care for 44.6 % of patients and worsened symptoms in 28.7 %. Additionally, 30.2 % of patients had seen a psychiatrist, and the prevalence of SI was significantly higher in this group. The study also explored the prevalence of SI with comorbidities and types of drugs used, finding no statistically significant differences. Conclusion: The study revealed a high prevalence of suicide ideation among MS patients, emphasizing the need for tailored comprehensive support. Factors contributing to SI included limited healthcare access, fear of COVID-19 complications, social isolation, and heightened anxiety. Recommendations for healthcare providers stress early diagnosis, personalized treatment plans, and collaborative efforts to enhance the well-being of individuals with MS in Iran post-COVID-19.

The impact of social and environmental factors on triggering multiple sclerosis onset, before and during the COVID-19 pandemic: a retrospective study from Iran

COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?

The effect of COVID-19 on Multiple Sclerosis relapse: A systematic review and meta-analysis

Exploring suicidal ideation prevalence in multiple sclerosis patients during the COVID-19 pandemic: A study on the relationship between drug use and suicidal ideation

Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases

Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies

Fear of re-infection, relapse, and anxiety during COVID-19 pandemic in patients with multiple sclerosis: A multi-center study

Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients

The Interaction between Viral and Environmental Risk Factors in the Pathogenesis of Multiple Sclerosis

Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999–2018

Prevalence and incidence of multiple sclerosis in Isfahan, Iran between 1996 and 2021: A population-based study

Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis

Predicting Multiple Sclerosis Outcomes During the COVID-19 Stay-at-home Period: Observational Study Using Passively Sensed Behaviors and Digital Phenotyping

Environmental factors related to multiple sclerosis progression

The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis

Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study

Effects of COVID-19 on Multiple Sclerosis Relapse: A Comprehensive Review

Correlation of multiple sclerosis (MS) incidence trends with solar and geomagnetic indices: time to revise the method of reporting MS epidemiological data

Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study

The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multiple Methods Study

COVID-19 and multiple sclerosis: challenges and lessons for patient care